Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concomitant use of strong CYP450 3A4 inducers with tretinoin (systemic) may decrease the plasma concentration of tretinoin, which is a CYP450 3A4 substrate. Reduced efficacy of tretinoin may occur. Studies document the interaction between endogenous retinoids and CYP450 3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital) showing decreased concentration of the retinoids and reduced efficacy. While clinical data specific to tretinoin are not available, similar effects may occur.

MANAGEMENT: The manufacturer recommends avoiding concomitant use of tretinoin with strong CYP450 3A4 inducers due to a potentially significant reduction in its efficacy.

Food enhances the absorption of rifapentine and may reduce the incidence of stomach upset, nausea, and/or vomiting. However, if rifapentine is part of a combination product, the recommendations may differ. Talk to your healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.